Changes in valganciclovir use among infants with congenital CMV diagnosis in the United States, 2009-2015 and 2016-2019
From 2009‒2015 to 2016‒2019, the proportion of U.S. infants with congenital cytomegalovirus (cCMV) treated with valganciclovir roughly doubled for infants enrolled with employer-sponsored insurance (from 16% to 29%) and Medicaid (from 16% to 36%). The proportion treated with valganciclovir increased for all cCMV disease severity groups.
source https://www.jpeds.com/article/S0022-3476(22)00292-X/fulltext?rss=yes
source https://www.jpeds.com/article/S0022-3476(22)00292-X/fulltext?rss=yes
Comments
Post a Comment